The European Medicines Agency (EMA) has accepted for review Fresenius Kabi`s Marketing Authorization Application (MAA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is another milestone for Fresenius Kabi following last year`s approval and launch of the company`s adalimumab biosimilar (Idacio®) in Europe. (* Neulasta® is a registered trademark of Amgen)

Attachments

  • Original document
  • Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 22 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2020 08:11:06 UTC